Silverarc Capital Management LLC Purchases 25,535 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Silverarc Capital Management LLC Purchases 25,535 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Silverarc Capital Management LLC grew its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) by 22.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 139,539 shares of the company's stock after purchasing an additional 25,535 shares during the quarter. Crinetics Pharmaceuticals makes up approximately 0.8% of Silverarc Capital Management LLC's portfolio, making the stock its 28th largest holding. Silverarc Capital Management LLC owned 0.26% of Crinetics Pharmaceuticals worth $2,602,000 as of its most recent filing with the Securities & Exchange Commission.
據Crinetics製藥公司(納斯達克代碼:CRNX-GET評級)在提交給美國證券交易委員會的最新披露中稱,該公司在第二季度的持股比例增加了22.4%。該公司在本季度額外購買了25,535股後,擁有139,539股公司股票。Crinetics製藥公司約佔SilverarcCapital Management LLC投資組合的0.8%,使該股成為其第28大持股。截至最近提交給美國證券交易委員會的文件,SilverarcCapital Management LLC擁有Crinetics PharmPharmticals 0.26%的股份,價值2,602,000美元。
A number of other institutional investors also recently modified their holdings of the company. Group One Trading L.P. increased its position in Crinetics Pharmaceuticals by 31.6% during the first quarter. Group One Trading L.P. now owns 7,318 shares of the company's stock worth $161,000 after acquiring an additional 1,759 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Crinetics Pharmaceuticals by 17.4% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,493 shares of the company's stock worth $164,000 after acquiring an additional 1,110 shares during the period. PDT Partners LLC bought a new position in Crinetics Pharmaceuticals during the first quarter worth $220,000. DekaBank Deutsche Girozentrale increased its position in Crinetics Pharmaceuticals by 9.7% during the first quarter. DekaBank Deutsche Girozentrale now owns 11,300 shares of the company's stock worth $215,000 after acquiring an additional 1,000 shares during the period. Finally, GSA Capital Partners LLP increased its position in Crinetics Pharmaceuticals by 20.8% during the first quarter. GSA Capital Partners LLP now owns 14,897 shares of the company's stock worth $327,000 after acquiring an additional 2,562 shares during the period. Institutional investors own 94.42% of the company's stock.
其他一些機構投資者最近也調整了對該公司的持股。第一集團貿易公司在第一季度將其在Crinetics製藥公司的頭寸增加了31.6%。Group One Trading L.P.在此期間增持了1,759股,現在擁有7,318股該公司股票,價值161,000美元。Zurcher Kantonalbank蘇黎世廣東銀行在第一季度將其在Crinetics PharmPharmticals的頭寸增加了17.4%。Zurcher Kantonalbank蘇黎世廣東銀行在此期間額外收購了1110股,現在擁有7493股該公司股票,價值16.4萬美元。PDT Partners LLC在第一季度購買了Crinetics PharmPharmticals的一個新頭寸,價值22萬美元。德意志銀行第一季度將其在Crinetics PharmPharmticals的頭寸增加了9.7%。DekaBank Deutsche Girozentale在此期間增持了1,000股,目前持有11,300股該公司股票,價值21.5萬美元。最後,GSA Capital Partners LLP在第一季度將其在Crinetics製藥公司的頭寸增加了20.8%。GSA Capital Partners LLP在此期間額外購買了2562股,現在擁有14,897股該公司股票,價值327,000美元。機構投資者持有該公司94.42%的股票。
Crinetics Pharmaceuticals Trading Down 3.0 %
Crinetics製藥公司股價下跌3.0%
Crinetics Pharmaceuticals stock traded down $0.58 on Wednesday, hitting $18.47. The company's stock had a trading volume of 4,668 shares, compared to its average volume of 248,631. The company has a fifty day moving average price of $20.33 and a 200-day moving average price of $20.11. Crinetics Pharmaceuticals, Inc. has a one year low of $15.91 and a one year high of $28.95.
週三,Crinetics PharmPharmticals的股價下跌0.58美元,觸及18.47美元。該公司股票的成交量為4,668股,而其平均成交量為248,631股。該公司的50日移動平均價為20.33美元,200日移動平均價為20.11美元。Crinetics PharmPharmticals,Inc.的一年低點為15.91美元,一年高位為28.95美元。
Insider Buying and Selling at Crinetics Pharmaceuticals
Crinetics PharmPharmticals的內幕買賣
Crinetics Pharmaceuticals Profile
Crinetics製藥公司簡介
(Get Rating)
(獲取評級)
Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs).
Crinetics製藥公司是一家臨牀階段製藥公司,專注於罕見內分泌疾病和內分泌相關腫瘤治療藥物的發現、開發和商業化。它的主要候選產品是Paltusotine,這是一種口服選擇性非肽生長抑素受體2型激動劑,已經完成了治療肢端肥大症的第三階段臨牀試驗,以及治療類癌綜合徵和無功能神經內分泌腫瘤(NETS)的第二階段臨牀試驗。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Crinetics Pharmaceuticals (CRNX)
- Hot Potato: Lamb Weston Stock Confirms a Top
- Too Soon: 3 Reasons to Wait on DocuSign Stock
- Rite-Aid Sings a Familiar Tune That Investors Don't Want to Hear
- Don't Give Up on These Q3 Losers
- The Anatomy of a Great Pension Plan
- 免費獲取StockNews.com的Crinetics PharmPharmticals研究報告(CRNX)
- 辣土豆:韋斯頓羊肉庫存漲幅居前
- 太快:等待DocuSign股票的三個理由
- 禮儀援助唱出了投資者不願聽到的熟悉曲調
- 不要放棄這些第三季度的失敗者
- 一個偉大的養老金計劃的剖析
Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《Crinetics PharmPharmticals Daily》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Crinetics製藥和相關公司的最新新聞和分析師評級的每日簡要摘要。